Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy

Urology

Volumn 59, Issue 2, 2002, Pages 256-260

  Tombal, Bertrand ^a   Querton, Michael ^a   De Nayer, Philippe ^a   Sauvage, Philippe ^a   Cosyns, Jean Pierre ^a   Feyaerts, Axel ^a   Opsomer, Renier ^a   Wese, François X ^a   Van Cangh, Paul J ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; ANALYSIS OF VARIANCE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; ROC CURVE; SURVIVAL ANALYSIS;

EID: 0036173517     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01515-1     Document Type: Article

References (27)

1. Prostate specific antigen; a decade of discovery-what we have learned and where we are going
2. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer
3. rostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml
4. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging
5. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer
6. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma
7. Nonpalpable stage T1c prostate cancer; prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings
8. Serum percent-free PSA does not predict extraprostatic spread of prostate cancer
9. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate
10. The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer
11. Use of percent free prostate-specific antigen as a predictor of the pathological features of clinically localized prostate cancer
12. The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer
13. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer
14. The use of percent free prostate specific antigen for staging clinically localized prostate cancer
15. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology
16. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA
17. Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy; a 13-year retrospective study of the incidence and natural history of T1a-T1b prostate cancers
18. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy; results from the Cancer of the Prostate Strategic Urologic Research Endeavor database
19. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy
20. Biological determinants of cancer progression in men with prostate cancer
21. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population
22. Significance of small foci of Gleason score 7 or greater prostate cancer on needle biopsy
23. Prostate cancer is highly predictable; a prognostic equation based on all morphological variables in radical prostatectomy specimens
24. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen; a prospective multicenter clinical trial
25. Natural history of progression after PSA elevation following radical prostatectomy
26. Localized prostate cancer; relationship of tumor volume to clinical significance for treatment of prostate cancer
27. Relationship between grade and stage of adenocarcinoma of the prostate and regional pelvic lymph node metastases